Sanofi reports positive Phase III results for a subcutaneous version of Sarclisa in relapsed or refractory multiple myeloma.

Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to ...

UK-based Alchemab Therapeutics, a biopharma seeking to identify and develop naturally occurring therapeutic antibodies from ...

Swiss oncology-focused Araris Biotech developing next-generation antibody drug conjugates (ADCs), today announced a research ...

UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on ...

Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and ...

German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief ...

AstraZeneca's Lynparza receives NICE approval for treating advanced breast cancer in England and Wales, backed by OlympiAD ...

Cambridge, USA-based biotech Sunbird Bio, which is developing proprietary blood-based technologies to improve diagnosis and ...

MaaT Pharma reports positive Phase III results for MaaT013, its microbiome-based therapy for gastrointestinal GvHD, achieving ...

AiCuris appoints Jacques Dumas as CSO to lead research efforts as the company refocuses on infectious disease therapies for ...

Angelini Ventures co-leads a $21 million series A round for Neumirna Therapeutics, supporting its RNA-based therapies for ...